DS
NBRV

David Shaw’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

David Shaw’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-79
Closed -$40K – 4261
2019
Q3 		$40K Buy
+79
New +$44.6K ﹤0.01% 3737
2019
Q2 		– Sell
-485
Closed -$296K – 3977
2019
Q1 		$296K Buy
+485
New +$265K ﹤0.01% 3223
2018
Q4 		– Sell
-103
Closed -$70K – 4110
2018
Q3 		$70K Buy
+103
New +$73K ﹤0.01% 3640
2017
Q4 		– Sell
-345
Closed -$706K – 3818
2017
Q3 		$706K Buy
+345
New +$809K ﹤0.01% 2711

Other funds holding NBRV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

David Shaw's NBRV Position: Q4 2019 in Review

David Shaw sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q4 2019, closing a stake of 79 shares — an estimated $40K sold.

David Shaw first reported a position in NBRV in Q3 2017 and held it in 4 quarters. The position peaked at $706K in Q3 2017. 50 funds tracked by Wall St. Rank hold NBRV as of Q4 2019.

  • David Shaw reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q4 2019 after selling out during the quarter.
  • David Shaw sold 79 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q4 2019, an estimated $40K.
  • David Shaw first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2017 and held it in 4 quarters.
  • David Shaw's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $706K in Q3 2017.
  • 50 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q4 2019.

Based on D.E. Shaw & Co's 13F filing for Q4 2019, filed 14 Feb 2020.